Trial Profile
An Open-label, Multi-center Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Sanofi
- 07 Sep 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 30 Sep 2023 to 18 Aug 2023.
- 09 May 2023 Planned End Date changed from 30 Aug 2023 to 30 Sep 2023.